EA201690937A1 - Композиции и способы лечения вирусных заболеваний с помощью модуляторов фдэ-4 (pde4) - Google Patents

Композиции и способы лечения вирусных заболеваний с помощью модуляторов фдэ-4 (pde4)

Info

Publication number
EA201690937A1
EA201690937A1 EA201690937A EA201690937A EA201690937A1 EA 201690937 A1 EA201690937 A1 EA 201690937A1 EA 201690937 A EA201690937 A EA 201690937A EA 201690937 A EA201690937 A EA 201690937A EA 201690937 A1 EA201690937 A1 EA 201690937A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pde
methods
pde4
modulators
compositions
Prior art date
Application number
EA201690937A
Other languages
English (en)
Inventor
Джером Б. Зелдис
Викрам Кхетани
Original Assignee
Селджин Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Селджин Корпорейшн filed Critical Селджин Корпорейшн
Publication of EA201690937A1 publication Critical patent/EA201690937A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Раскрываются способы лечения и/или предупреждения вирусных заболеваний и состояний, таких как заболевания и состояния, интенсивность которых уменьшается ингибированием активности ФДЭ-4.
EA201690937A 2013-11-06 2014-11-05 Композиции и способы лечения вирусных заболеваний с помощью модуляторов фдэ-4 (pde4) EA201690937A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361900489P 2013-11-06 2013-11-06
PCT/US2014/064047 WO2015069711A1 (en) 2013-11-06 2014-11-05 Compositions and methods for the treatment of viral diseases with pde4 modulators

Publications (1)

Publication Number Publication Date
EA201690937A1 true EA201690937A1 (ru) 2017-02-28

Family

ID=51999519

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690937A EA201690937A1 (ru) 2013-11-06 2014-11-05 Композиции и способы лечения вирусных заболеваний с помощью модуляторов фдэ-4 (pde4)

Country Status (14)

Country Link
US (1) US20160289188A1 (ru)
EP (1) EP3065778A1 (ru)
JP (1) JP2016540041A (ru)
KR (1) KR20160068981A (ru)
CN (1) CN105873611A (ru)
AR (1) AR099283A1 (ru)
AU (1) AU2014346877A1 (ru)
CA (1) CA2929539A1 (ru)
EA (1) EA201690937A1 (ru)
IL (1) IL245511A0 (ru)
MX (1) MX2016005808A (ru)
PH (1) PH12016500824A1 (ru)
SG (1) SG11201603469UA (ru)
WO (1) WO2015069711A1 (ru)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605914A (en) * 1993-07-02 1997-02-25 Celgene Corporation Imides
MXPA05005161A (es) * 2002-11-18 2005-07-22 Celgene Corp Metodos de utilizacion y composiciones que comprenden (-)3- (3, 4-dimetoxi- fenil)-3 -(1-oxo -1, 3-dihidro- isoindol- 2-il)- propionamida.
CN1452982A (zh) * 2003-06-25 2003-11-05 上海兴康医药研究开发有限公司 用于预防sars的利巴韦林黏膜给药制剂及制备方法
CN1972684A (zh) * 2004-04-23 2007-05-30 细胞基因公司 用于治疗和控制肺高血压的含有pde4调节剂的组合物以及其使用方法
WO2007139150A1 (ja) * 2006-05-30 2007-12-06 The University Of Tokushima ＴＮＦα阻害物質を含有してなる抗インフルエンザウイルス剤
MX2010002278A (es) * 2007-08-27 2010-03-17 Siga Technologies Inc Farmacos antivirales para el tratamiento de una infeccion por arenavirus.
US20100080807A1 (en) * 2008-09-26 2010-04-01 National Taiwan University Methods and Compositions for Treating Viral Hemorrhagic Fever
US20100297033A1 (en) * 2009-05-21 2010-11-25 Mcleay Matthew T Megaribavirin alone or combination of other antiviral, antioxidant and a perflubron emulsion for treatment of viral disease
US9408831B2 (en) * 2010-04-07 2016-08-09 Celgene Corporation Methods for treating respiratory viral infection
WO2012118599A1 (en) * 2011-02-28 2012-09-07 Emory University C-abl tyrosine kinase inhibitors useful for inhibiting filovirus replication

Also Published As

Publication number Publication date
JP2016540041A (ja) 2016-12-22
US20160289188A1 (en) 2016-10-06
SG11201603469UA (en) 2016-05-30
IL245511A0 (en) 2016-06-30
WO2015069711A1 (en) 2015-05-14
CA2929539A1 (en) 2015-05-14
KR20160068981A (ko) 2016-06-15
AU2014346877A1 (en) 2016-05-26
MX2016005808A (es) 2016-07-18
EP3065778A1 (en) 2016-09-14
AR099283A1 (es) 2016-07-13
CN105873611A (zh) 2016-08-17
PH12016500824A1 (en) 2016-06-13

Similar Documents

Publication Publication Date Title
EA201690306A1 (ru) Ингибиторы ido
EA201591599A1 (ru) Ингибиторы ido
EA201690152A1 (ru) Ингибиторы ido
EA201790806A1 (ru) Иммунорегулирующие средства
EA201690027A1 (ru) Ингибиторы ido
EA201790998A1 (ru) Иммуннорегуляторные агенты
EA201792204A1 (ru) Ингибиторы ido
EA201591823A1 (ru) Ингибиторы ido
EA201791628A1 (ru) Терапевтические циклические соединения в качестве иммуномодуляторов
EA201792354A1 (ru) Композиции обетихолевой кислоты и способы применения
EA201492219A1 (ru) Соединения и композиции для модуляции egfr активности
EA201690316A1 (ru) Соединения для применения в качестве иммуномодуляторов
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201691135A1 (ru) Новые ингибиторы глутаминазы
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
EA201991071A1 (ru) Композиции и способы для лечения ezh2-опосредованного рака
EA201591746A1 (ru) Способы и композиции для ингибирования бромодомен-содержащих белков
EA201591382A1 (ru) Ингибиторы гистондеметилаз
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
EA201491953A1 (ru) СОЕДИНЕНИЯ НА ОСНОВЕ МИКРОРНК И СПОСОБЫ МОДУЛИРОВАНИЯ АКТИВНОСТИ miR-21
EA201492002A1 (ru) Противовирусные соединения
EA201891251A1 (ru) Бициклические ингибиторы pad4
EA201591278A1 (ru) Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы